Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years

2019 ◽  
Vol 153 (3) ◽  
pp. 479-486 ◽  
Author(s):  
Paul A. DiSilvestro
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Oncology ◽  
Standard Of Care ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Cancer Management ◽  
The Past ◽  
Oncology Clinical Trials

scholarly journals Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer

2004 ◽  
Vol 2 (6) ◽  
pp. 555-560 ◽  
Author(s):  
Robert F. Ozols
Keyword(s):  
Ovarian Cancer ◽  
Standard Therapy ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Standard Of Care ◽  
Systemic Circulation ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Phase Ii Trials

Intraperitoneal (IP) chemotherapy in ovarian cancer has been studied since 1978. Numerous phase II trials have been performed, which have shown that higher levels can be obtained in the peritoneal cavity compared with systemic circulation after administration of cytoxic agents in a large volume via a semi-permanent catheter. Three randomized trials have been performed in patients with ovarian cancer comparing different IP regimens to standard therapy with intravenous agents. The last two trials from the Gynecologic Oncology Group (GOG) and the Southwest Oncology Group (SWOG) compared two different IP regimens versus standard therapy with intravenous cisplatin plus paclitaxel. Although an improvement in progression-free survival was reported for the IP regimens, they have been associated with unacceptable toxicity, and no IP regimen can be considered standard therapy. Maintenance therapy with IP cisplatin also failed to improve survival in patients who obtained complete remission after intravenous chemotherapy. The GOG is considering another phase III trial of IP therapy that will compare a carboplatin-based regimen versus standard therapy with intravenous paclitaxel plus carboplatin. Unless such a trial shows an improvement in clinical outcome, intravenous carboplatin plus paclitaxel remains the standard of care and IP chemotherapy should not be used outside of a clinical trial.

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

2006 ◽  
Vol 101 (3) ◽  
pp. 390-397 ◽  
Author(s):  
Angeles Alvarez Secord ◽  
Paula S. Lee ◽  
Kathleen M. Darcy ◽  
Laura J. Havrilesky ◽  
Lisa A. Grace ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Poor Prognosis ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Maspin Expression

scholarly journals Localized ovarian cancer in the elderly: The gynecologic oncology group experience

Cancer ◽  
2010 ◽  
Vol 71 (S2) ◽  
pp. 601-605 ◽  
Author(s):  
Robert C. Young ◽  
Mark F. Brady ◽  
Leslie A. Walton ◽  
Howard D. Homesley ◽  
Hervy E. Averette ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
The Elderly ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Group Experience
Sign in / Sign up

Export Citation Format

Share Document